The inhibitor of the Janus kinases 1 and 2 ruxolitinib is currently approved for primary and certain secondary forms of myelofibrosis, hydroxyurea resistant polycythemia vera, and for graft versus host disease (GvHD) in steroid refractory patients [43–45]. The gene discussed is JAK1; the disease is graft versus host disease.